International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: https://doi.org/10.5281/zenodo.13990805
Original Research Article
Evaluating Serum Calcium and Albumin as Prognostic Biomarkers in Acute Ischemic Stroke Outcomes: A Cross-Sectional Study at Mandya Institute of Medical Sciences
Published
Oct. 25, 2025
Abstract

Background: Acute ischemic stroke (AIS) remains a leading cause of morbidity and mortality worldwide. Rapid and accurate prognostic assessment can significantly influence management and outcomes. Serum albumin and calcium are accessible biomarkers that could provide prognostic information on stroke severity and recovery.Methods: This cross-sectional study included 120 patients admitted with AIS at the Mandya Institute of Medical Sciences. Serum levels of albumin and calcium were measured upon admission and correlated with the National Institutes of Health Stroke Scale (NIHSS) scores and Barthel Index for assessing neurological severity and functional outcomes.Results: Lower serum levels of albumin and calcium were significantly associated with higher NIHSS scores at admission (p < 0.01 and p < 0.05, respectively). Patients with severe strokes had mean albumin levels of 3.2 g/dL and mean calcium levels of 7.3 mg/dL. Moreover, recovery, as indicated by improvements in NIHSS scores, showed a significant positive correlation with higher levels of albumin (correlation coefficient = 0.62, p < 0.001) and calcium (correlation coefficient = 0.59, p < 0.001).Conclusion: Serum albumin and calcium levels are significant prognostic biomarkers in AIS, correlating with the severity of stroke and recovery outcomes. Their routine assessment can aid in early prognosis and potentially guide therapeutic decisions, particularly in resource-constrained environments.

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
2482 Views
341 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved